Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $9.00 price target on the stock.

CNTX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Finally, JMP Securities began coverage on Context Therapeutics in a report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Context Therapeutics has a consensus rating of “Buy” and a consensus price target of $6.33.

Context Therapeutics Price Performance

CNTX opened at $0.98 on Wednesday. Context Therapeutics has a 12-month low of $0.89 and a 12-month high of $2.75. The business’s fifty day simple moving average is $1.40 and its 200-day simple moving average is $1.90.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). Equities analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after purchasing an additional 25,300 shares during the period. Ally Bridge Group NY LLC boosted its position in Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after buying an additional 1,160,281 shares during the last quarter. Great Point Partners LLC acquired a new position in Context Therapeutics in the 2nd quarter worth approximately $14,876,000. Affinity Asset Advisors LLC raised its position in Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after buying an additional 1,290,323 shares during the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new stake in Context Therapeutics during the 2nd quarter valued at approximately $10,348,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.